CD8A and neoplasm: Beyond its anti-tumor properties, eribulin has been observed to enhance the cytotoxic response of CD8-positive lymphocytes [3] and activate cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING)-mediated immune responses [4], thereby boosting overall cytotoxic immune activity [5,6].